Table 1. Cases with concordant results for detection of BCR-ABL1 fusion transcripts using the BML and in-house methods.

Patient #	Timing of detection	IS % ratio		TKI type after recurrence
	(month)	BML method	In-house method
6	9	0.01	0.0289	Dasatinib
7	2	0.04	0.0621	Imatinib
8	1	0.02	0.0259	Dasatinib
9	3	0.20	0.4548	Dasatinib
10	1	0.02	0.0648	Dasatinib
11	1	0.96	0.4306	Dasatinib
12	2	0.13	0.0700	Imatinib
13	1	0.01	0.0121	Dasatinib
14	3	0.01	0.0069	Dasatinib
15	1	<0.01	0.0093	Imatinib
16	1	0.04	0.0081	Dasatinib
17	3	0.16	0.2517	Dasatinib
18	2	0.05	0.0292	Imatinib
19	2	0.02	0.0672	Imatinib
20	5	0.03	0.1236	Dasatinib

IS, International scale.

Timing of detection: time point when BCR-ABL1 fusion transcripts were detected.